Context Therapeutics (CNTX) Proxy Filing summary

Executive summary

• Special Meeting scheduled for September 17, 2024, to be held virtually, with voting accessible online for all shareholders.

• Main agenda: approve an amendment to increase authorized common stock from 100,000,000 to 200,000,000 shares and allow adjournment if more time is needed to solicit votes.

• Board believes the increase is necessary for future flexibility in capital raising, business expansion, and equity compensation.

• Proxy materials are distributed electronically to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Proposal 1: Approve amendment to increase authorized common stock to 200,000,000 shares.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies or if quorum is not met.

• Both proposals are considered routine matters, allowing brokers to vote at their discretion if no instructions are given.

• Stockholders can vote online, by phone, or by mail, and may change their vote at any time before the meeting.

• Stockholder proposals for the 2025 annual meeting must be submitted by December 27, 2024.

Board of directors and corporate governance

• Board recommends voting in favor of both proposals.

• Board retains the right not to proceed with the amendment even if approved by shareholders.

• Certain provisions in the bylaws and certificate of incorporation may have anti-takeover effects, including board authority to issue preferred stock and requirements for supermajority votes to amend key provisions.